Gut microbiome dysbiosis and cancer: A systematic review on the emerging role of probiotics in oncology.

Crit Rev Oncol HematolJun 2, 2026 (epub)
Clinical ResearchOncology (Medical)Gastroenterology

Marjan Salehi, Andrea Gottardo, Tancredi Didier Bazan Russo et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review evaluated the impact of probiotic supplementation in cancer patients, focusing on its clinical effects. The review included various studies, revealing that probiotics were associated with a reduction in clinically relevant diarrhea, particularly severe cases, during chemotherapy. Additionally, probiotics showed potential benefits in gastrointestinal recovery post-surgery.

Key findings

  • Probiotic supplementation reduced clinically relevant diarrhea in chemotherapy patients.
  • Meta-analyses indicated improvements in gastrointestinal symptoms like nausea and bloating.
  • In colorectal surgery, probiotics were linked to fewer postoperative infections and shorter hospital stays.

Why it matters

Understanding the role of probiotics in managing gastrointestinal toxicity and recovery in cancer patients can enhance supportive care strategies, potentially improving patient outcomes during treatment and recovery phases.

What to keep in mind

Heterogeneity in study designs, formulations, and outcome definitions; few large-scale trials; limited reporting on adverse events.

Source

PubMed · PMID 42235902

Published in Crit Rev Oncol Hematol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.